Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07286929

Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma

The goal of modern neurooncological surgery is to obtain maximum tumor resection while preserving neurological function. Parietal lobe gliomas often cause attention deficits (hemineglect) that are difficult to differentiate from other deficits. This study aims to evaluate the extent and variation over time of visuo-spatial deficits in patients undergoing surgical removal of parietal lobe gliomas. This will help characterize the cognitive profile of these patients to identify personalized treatment and rehabilitation paths.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Italy

Location status: Recruiting

Location contact

Francesco Di Meco, MD

CONTACT

[email protected]

+ 39 02.2394

About this study

This is a single-centre, prospective, cross-sectional, observational study involving 40 patients with high- and low-grade parietal lobe glioma. The study investigates the prevalence of subjects who show a performance in cognitive visuo-spatial tests below the cut-off of the normative sample. It evaluates associations with patient-reported outcome measures (ADL, IADL), clinical-demographic aspects, radiological data (MRI), and histological/molecular data. Assessments occur at screening (pre-surgery), and at follow-up visits (3-4 months and 6 months post-surgery). Neuropsychological tests include Line Bisection, Bell and Letter Cancellation, Reading test, Apple Cancellation, and Fluff test.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients >18 years old
  • Patients must understand the Italian Language
  • Patients with suspected parietal lobe glioma

Exclusion criteria

  • Tumor site other than parietal lobe.
  • Patients who cannot undergo surgical resection (stereotactic/open biopsy).
  • Patients who received a previous chemotherapy and/or radiotherapy treatment.
  • Patients with a history of intracranial mass lesion or traumatic brain injury.
  • Patients with a history of other CNS diseases (e.g., stroke, metastasis).
  • Patients with diagnosis of neurodegenerative disease (i.e. Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis).

Treatment and study plan

Primary outcomes

  1. Change in Visuospatial Deficit Prevalence

    Time frame: Baseline (pre-surgery), 3-4 months post-surgery, 6 months post-surgery.

    Prevalence of patients with a score below the cut-off in specific neuropsychological tests for visuo-spatial aspects (Line Bisection, Bell/Letter Cancellation, Apple Cancellation, Fluff Test) and the extent of change compared to baseline.

Secondary outcomes

  1. Association with Radiological Data

    Time frame: Up to 6 months post-surgery

    Correlation between visuo-spatial deficit scores and MRI data (FLAIR volume, T1 contrast, necrosis, localization).

  2. Association with Clinical-Demographic Data

    Time frame: Up to 6 months post-surgery.

    Correlation between visuo-spatial scores and hemispheric dominance, age, sex, and education.

  3. Association with Performance Status

    Time frame: Time Frame: Up to 6 months post-surgery.

    Correlation between visuo-spatial scores and Karnofsky Performance Status (KPS).

  4. Association with Histological/Molecular Data

    Time frame: Up to 6 months post-surgery.

    Correlation between visuo-spatial scores and tumor grade, histological and molecular features.

Study contacts

Contact information is provided by the study sponsor or research team.

Francesco Di Meco, MD

CONTACT

[email protected]

+ 39 02.2394

Sponsors and collaborators

Lead sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Other

Registry information

Acronym: neGLIO

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Dec 16, 2025
Registry last updated
Dec 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.